English | 简体中文 | 繁體中文 | 한국어
Share:
Lubrizol LifeSciences to Showcase Full-Service Medical Device Solutions at MD&M West 2018
Lubrizol LifeSciences to Showcase Full-Service Medical Device Solutions at MD&M West 2018

News Release

Lubrizol LifeSciences to Showcase Full-Service
Medical Device Solutions at MD&M West 2018

CLEVELAND, February 6, 2018 -The Lubrizol Corporation's LifeSciences business will showcase its total solutions capabilities for medical device manufacturers at the MD&M West 2018 Exposition (Booth #2201), February 6-8. Lubrizol LifeSciences is a preferred medical device and pharmaceutical solutions partner, helping customers from concept to commercialization by offering polymer customization, drug-eluting device development and contract manufacturing services. This year, Lubrizol LifeSciences will highlight a strong commitment to the interventional catheters, long-term implant and drug-eluting device markets.

LifeSciences has invested significantly to expand its global development and manufacturing facilities to better serve the growing medical device market by expanding its silicone and thermoplastic capacity with a 71,000-square foot facility.  This facility features enhanced product development capabilities, cellular manufacturing and high-efficiency production lines in Class 7 & 8 clean rooms.

"When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process," states Uwe Winzen, general manager, Lubrizol LifeSciences. "Our long history of polymer expertise and medical device manufacturing, enhanced with recent investments, makes Lubrizol LifeSciences a full-service development partner for the next generation of medical devices, including long-term implantable and drug-eluting device innovations."

Additionally, at MD&M West LifeSciences will highlight a comprehensive suite of services focused on the development of advanced drug/device combination solutions including analytical services for coating characterization, drug release testing and more. LifeSciences is a preferred partner to take a novel device concept and expedite time to market with streamlined product development, clinical and commercial manufacturing capabilities.

About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,300 employees worldwide. Revenues for 2016 were $6.5 billion. For more information, visit Lubrizol.com.

Media Contact
Ben Patti
(216) 447-5827
www.lubrizol.com/LifeSciences

###





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract  
Feb 23, 2018 07:15 ET
Heijmans annual results 2017: sound basis for continued recovery  
Feb 23, 2018 07:12 ET
SeaBird Exploration: Fourth quarter 2017 report  
Feb 23, 2018 07:00 ET
SIKA ACHIEVES RECORD RESULTS IN 2017  
Feb 23, 2018 05:00 ET
Galapagos delivered in 2017  
Feb 22, 2018 22:01 ET
JCPenney Launches Obsess, a Totally Fun, Totally Stylish Tween Brand  
Feb 22, 2018 01:33 ET
Lubrizol Expands Global Capabilities and TPU Capacity  
Feb 20, 2018 20:03 ET
INGREDION'S UNIQUE VALUE PROPOSITION - A WINNING RECIPE; EXECUTIVES WILL PRESENT AT CAGNY 2018 CONFERENCE  
Feb 20, 2018 19:03 ET
Enterprise CPaaS spend set to quadruple to $6.7bn by 2022, estimates Juniper Research  
Feb 20, 2018 18:03 ET
CLX Communications & DeviceRadio Partner to Simplify Production & Launch of IoT devices  
Feb 20, 2018 03:03 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: